|
11/24/2008 09:00 PM
|
|
Pioneering Research Improves Accuracy Of Colorectal Cancer Staging
|
SANTA MONICA, Calif. -- Results of a pioneering study led by researchers at the John Wayne Cancer Institute at Saint John's Health Center show that sensitive molecular diagnostic techniques can effectively upstage early stage colorectal cancer patients believed to be cancer-free according to conventional methods. The findings could lead to more sensitive cancer detection, as well as more consistent ways of identifying patients who would benefit most from adjuvant therapy after surgery for colorectal cancer. The study, "Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial," was published in the November, 2008 edition of the journal Clinic...
|
|
11/13/2008 09:00 PM
|
|
OncoVAX, Other Vaccines Provide Hope For Colorectal Cancer Treatment, Prevention
|
NEW YORK, NY -- Propelled by advances in molecular biology, the treatment of colorectal cancer is on the verge of dramatic change and a promising future as innovative vaccines will replace chemotherapy. According to a new report from Kalorama Information, "Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis," this market, lead by OncoVAX, is poised for unprecedented growth, creating countless opportunities for market participants. More than 1.2 million cases of colon cancer are diagnosed worldwide each year with more than 529,000 deaths, which displays a considerable medical need. In the United States colorectal cancer is the second most common cause of cancer, accounting for approximately 50,000 d...
|
|
11/10/2008 09:00 PM
|
|
Correlative Study of Microvessel Density And 5-Lipoxygenase Expression in Human Sporadic Colorectal Cancer
|
Arachidonic acid, a fatty acid mainly derived from dietary sources, is metabolized by 3 major pathways: (1) the cyclooxygenase pathway, which leads to the formation of prostaglandins (PGs); (2) the lipoxygenase (LO) pathway, which forms hydroperoxyeicosatetraenoic acids, hydroxyeicosatetraenoic acids, and leukotrienes; and (3) the cytochrome P-450 monooxygenase pathway, which leads to the formation of epoxydes.1 Three major LOs have been characterized in human tissues. They have been named 5-LO, 12-LO, and 15-LO for their ability to insert molecular oxygen at the 5, 12, or 15 carbon atom of arachidonic acid. These enzymes have been demonstrated to exert a protumorigenic role in human neoplasias. Indeed, the significant elevation of th...
|
|
11/06/2008 09:00 PM
|
|
Dendreon Presents Integrated Analysis Of Clinical Data From Neuvenge Trials At Chemotherapy Foundation Symposium
|
SEATTLE -- Dendreon Corporation today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, which integrates the data from two clinical trials, highlights the safety profile, immune response and clinical activity of NEUVENGE in patients with HER2/neu-positive cancer who have failed standard therapy. "We are encouraged by the significant immune responses generated to NEUVENGE in these trials, which included patients with advanced breast, ovarian and colon cancer," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of Califo...
|
|
11/03/2008 09:00 PM
|
|
NCCN Announces New Updates To The NCCN Guidelines For Colon And Rectal Cancers
|
FORT WASHINGTON, Pa. -- The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Guidelines on Colon and Rectal Cancers. These changes reflect leading developments in the treatment of patients with colon and rectal cancers and represent the standard of care in oncology in both community and academic settings. New to the NCCN Guidelines is the recommendation that a determination of the KRAS gene status of either the primary tumor or a site of metastasis should be part of the pre-treatment work-up for all patients diagnosed with metastatic colorectal cancer. Another important update to the NCCN Guidelines is that the epidermal growth factor receptor (EGFR) inhibitors, cetuximab (Erbitux(R),...
|